Share

    


Home / Search Results

Search Results

Search Publications

Search Again?

Filter By Content Type

Filter By Topic

You searched for:

The Role of Liquid Biopsies in Modern Oncology Jean Bustamante MD MS 10/26/2023 Upper East Side Medical Oncology New York Cancer and Blood Specialists Learning objectives: -Understand the importance of molecular testing in solid tumors. -Identify the right patient and the right setting to use liquid biopsies. -Understand the different platforms used and how to leverage …
Asonganyi-Zinkeng-Spring-2022-ORM Improving Your Formulary and Denials Management Zinkeng Asonganyi, PharmD Director of Pharmacy Services-Ambulatory Operations University of Texas Medical Branch Objectives • Understand the data and metrics your cancer program or practice must collect and report on to improve revenue cycle management, eliminate waste, and reduce …
PowerPoint Presentation Improving Your Formulary and Denials Management Zinkeng Asonganyi, PharmD Director of Pharmacy Services-Ambulatory Operations University of Texas Medical Branch Objectives Understand the data and metrics your cancer program or practice must collect and report on to improve revenue cycle management, eliminate waste, and reduce costs. Gain insight on how to use these …
Challenging Cases in Classical Hematology Hillary Maitland MD MS Disclosures • Sanofi • Sobi Case 1 • Ms. A: 57 yo woman with metastatic HR+/HER2+ breast cancer metastatic to the brain. She comes in for her Enhertu infusion and complains of right calf pain and swelling. Case 1 Case 1 • DVT in R common femoral vein extending into the proximal …
TITLE OF PRESENTATION ONCOLOGY HEALTH DISPARITIES IN WISCONSIN Kirsten Beyer, PhD, MPH, MS; Associate Professor, Medical College of Wisconsin Wisconsin Association of Hematology and Oncology Annual Conference Hilton Milwaukee City Center; Milwaukee, WI September 24, 2022 DISCLOSURE OF CONFLICTS OF INTEREST • Kristen Beyer, PhD, MPH, MS, has no relevant financial relationships to …
PowerPoint Presentation Exploring Hereditary Syndromes Samantha Hall, FNP-C, AOCNP Disclosures • I have no disclosures Objective • Following this lecture, participants should be able to discuss testing criteria for and management of common hereditary cancer syndromes Overview • All cancers develop because of a pathogenic mutation in one or more …
Triple Negative Breast Cancer: SABCS 2023 Updates Malinda West, MS, MD Assistant Professor, Breast Medical Oncology Department of Medicine, University of Wisconsin, Madison February 3, 2024 Disclosures I have no conflicts of interest to disclose Learning objectives 1. Identify the potential role of ICI (pembrolizumab) and parp inhibition in BRCA wild-type …
Observed 2010-2014 Annual percentage change: 1.55 (95% CI -1.2 to 4.4, P=0.2) Choose rasburicase: Recommended for patients at intermediate and high risk for development of TLS associated with hyperuricemia.4 Dear Healthcare Provider, Tumor lysis syndrome (TLS)—related hyperuricemia is an oncologic emergency that can be avoided with proactive management. Between 2010-2014, 37.1% of patients …
HSCO 10.21.23 Attendee Roster - 10.11.xlsx HSCO 2023 Annual Conference October 21st, 2023 Kahala Hotel Resort Honolulu, HI Attendee Roster First Name Last Name Title Account Name Diana Vucurevich NP Adventist Health Castle Aaron Segel State Advocacy Specialist American Society of Clinical Oncology (ASCO) Lisa Tang Senior Oncology Specialist Amgen Oncology Robert Jester Apellis …
1. Instructions Component RO MODEL PROFESSIONAL COMPONENT WORK BOOK INSTRUCTIONS This work book is designed to assist RO Model participants as they determine the impact of the RO Model on practice revenues. In order to complete this work book, each RO Model participant must follow these steps: Once RO Model participants have identified the data points below, they should complete …
LO C A LL Y A D V A N C ED O R M ET A ST A T IC BBTTCCs with IMFINZI + gem-cis BEYONDREACH treatment of locally advanced or metastatic BTCs PRESCRIBED IN FIRST-LINE1# Data are based on total US patients treated with IMFINZI vs non-IMFINZI in 1L from September 2022 to January 2024. Reference: Data on File, US-88164, AstraZeneca Pharmaceuticals LP; …
CML-FinalReport-2011-appendix1
ICLIO eCourse Immuno-Oncology: Coverage and Reimbursement Navigating Immuno-Oncology Coverage & Reimbursement Issues Niesha Griffith, RPh, MS, FASHP Administrator of Oncology Pharmacy and Infusion Services at the Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at The Ohio State University Bill McGivney, PhD Principal of McGivney Global Advisors ICLIO …
ICLIO eCourse Immuno-Oncology: Coverage and Reimbursement Navigating Immuno-Oncology Coverage & Reimbursement Issues Niesha Griffith, RPh, MS, FASHP Administrator of Oncology Pharmacy and Infusion Services at the Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at The Ohio State University Bill McGivney, PhD …
ONCOLOGY HEALTH DISPARITIES IN WISCONSIN Kirsten Beyer, PhD, MPH, MS; Associate Professor, Medical College of Wisconsin Wisconsin Association of Hematology and Oncology Annual Conference Hilton Milwaukee City Center; Milwaukee, WI September 24, 2022 DISCLOSURE OF CONFLICTS OF INTEREST • Kristen Beyer, PhD, MPH, MS, has no relevant financial relationships to disclose. OVERVIEW …
Urologic Oncology Update Urologic Oncology Trends Samuel Deem, DO, MBA, FACOS Urology Residency Program Director Director of Robotic Surgery Overview • Prostate Cancer #3 WV (288,300 dx, 34,700 deaths) • Bladder Cancer #5 WV (82,290 dx, 16,710 deaths) • Kidney Cancer #7 WV (81,800 dx, 14,890 deaths) • Penile/Testicular Cancer • Adrenal Cancer • I have nothing to …
PowerPoint Presentation Metastatic Colon Cancer Dulabh K. Monga MD Associate Professor of Medicine Drexel University School of Medicine Allegheny Health Network Cancer Institute Pittsburgh Disclosures Speakers Bureau: Bristol Myers Squibb Astra Zeneca Advisory Board: Astra Zeneca Key Studies in Metastatic Colorectal Cancer ASCO 2024 ➢ Checkmate …
PHASE Ib PILOT STUDY OF ITACITINIB WITH ALEMTUZUMAB IN PATIENTS WITH T-CELL PROLYMPHOCYTIC LEUKEMIA Kadia T, Jain A, Ravandi F, Borthakur G, Jabbour E, Montalban-Bravo G, Adewale L, Pierce S, Lacke C, Brandt M, Short N, Jain N, Burger J, Ferrajoli A, Wierda W, Kantarjian H Presenter:- Akhil Jain, MD Fellow, Holden Comprehensive Cancer Center Disclosure- none Background …
PowerPoint Presentation Acute Myeloid Leukemia Patients in Complete Remission with Positive Measurable Residual Disease Prior to Allogeneic Transplant Have Worse Outcomes, Similar to Active Disease Regardless of Conditioning Regimen Intensity and Post-Transplant Cyclophosphamide Administration Pavan Tenneti, MD , Jiaxian He, MS , Brittany Knick Ragon, MD , Nilay A. Shah, MD , Jing Ai, …
keytruda_mg.pdf MEDICATION GUIDE KEYTRUDA ® (key-true-duh) (pembrolizumab) injection What is the most important information I should know about KEYTRUDA? KEYTRUDA is a medicine that may treat certain cancers by working with your immune system. KEYTRUDA can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they …